<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024827</url>
  </required_header>
  <id_info>
    <org_study_id>CARE-E-01</org_study_id>
    <nct_id>NCT03024827</nct_id>
  </id_info>
  <brief_title>Cannabidiol in Children With Refractory Epileptic Encephalopathy</brief_title>
  <acronym>CARE-E</acronym>
  <official_title>Cannabidiol in Children With Refractory Epileptic Encephalopathy: A Phase 1 Open Label Dose Escalation Study (CARE-E)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of a cannabidiol-enriched Cannabis Herbal
      Extract in a small group of children with refractory epileptic encephalopathy. The dosage of
      Cannabis Herbal Extract will be gradually increased over a four month time period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epileptic Encephalopathies are a group of epilepsies that develop in children. These
      epilepsies can cause frequent and difficult to control seizures. Because of the ongoing
      seizures, these epilepsies can also cause cognitive impairment and neurological impairment.

      In many children with these Epileptic Encephalopathies, seizures are difficult to control
      with medical treatment, such as anti-convulsants or non-drug treatments like the ketogenic
      diet (a high fat, adequate-protein, low-carbohydrate diet). This has resulted in a need to
      find therapies that are effective and better tolerated for children with epileptic
      encephalopathies.

      There is very limited data regarding the use of cannabis products in children, in particular
      cannabidiol-enriched cannabis oil in children with epilepsy. However, hemp oil products with
      high cannabidiol and low tetrahydrocannabinol ratios have been reported to provide seizure
      relief and cognitive improvement in children who take them.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Blood Count (CBC) and Differential</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium, potassium, chloride, calcium, magnesium, phosphate and carbon dioxide (mmol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Urea Nitrogen (mmol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine (umol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Gamma-glutamyl transferase (GGT) and Lipase (U/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total and Direct Bilirubin (umol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin (g/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol and Triglyceride (mmol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clobazam and Norclobazam Levels (umol/L)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>For participants taking clobazam who become excessively sedated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Ketones</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>For participants on the ketogenic diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Level of Concomitant Anti-Convulsants</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Measure interactions with any anti-convulsants participants may be already on</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, up to 7 months</time_frame>
    <description>Side effect rating scale, includes items related to sleepiness/lethargy, irritability, nausea/vomiting and diarrhea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2-hour Electroencephalogram (EEG) Recording</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure Frequency Log Book</measure>
    <time_frame>Through study completion, up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Quality of Life in Children with Epilepsy Questionnaire (QOLCE)</measure>
    <time_frame>Through study completion, up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabidiol (CBD) (ng/mL)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Levels in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tetrahydrocannabinol (Δ9-THC) (ng/mL)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Levels in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11-nor-9-carboxy-tetrahydrocannabinol (11-nor-9-Carboxy-THC) (ng/mL)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Levels in blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epileptic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Medical Cannabis Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CanniMed® 1:20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CanniMed® 1:20</intervention_name>
    <description>A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.</description>
    <arm_group_label>Medical Cannabis Oil</arm_group_label>
    <other_name>Medical Cannabis Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 1-10 years

          -  Epileptic Encephalopathy

          -  A minimum of at least 1 major seizure per week or 4 major seizures per month. For the
             purposes of this research study, a major seizure would include atonic, tonic, clonic,
             tonic-clonic, major myoclonic, myoclonic astatic seizures and epileptic spasms
             (including infantile spasms)

          -  Refractory to anticonvulsant medication as per the International League Against
             Epilepsy (ILAE) Definition of failing 2 appropriate anticonvulsants at therapeutic
             doses

          -  The ability to attend appointments regularly

          -  Negative pregnancy test at screening for females who have reached menarche

        Exclusion Criteria:

          -  Recent (&lt;1 month) change in anticonvulsant therapies including anticonvulsant
             medications, ketogenic diet or settings on Vagal Nerve Stimulator

          -  Initiation of ketogenic diet within 6 months (Patients must be on the ketogenic diet
             for at least 6 months to prevent any delayed response from the ketogenic diet
             affecting study results)

          -  Implantation and activation of Vagal Nerve Stimulator within 12 months (Patients may
             have a vagal nerve stimulator for at least one year once again to prevent delayed
             response from the vagal nerve stimulator affecting study results)

          -  Use of cannabis-based therapy within 2 months (Participants who have previously used
             a cannabis based therapy may be included if they have a 2 month period without use of
             cannabis based therapy prior to enrolment in the study)

          -  Use of selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant or
             atypical neuroleptic medication in last month

          -  Concomitant regular use of narcotics (Use of narcotics in emergency situations and
             supervised by a physician is allowed)

          -  Initiation or dosage change of oral or injected steroids within 3 months

          -  Allergy or known intolerance to any of the compounds within the study preparation

          -  Inability of study participants to attend assessments on a monthly basis

          -  Clinically significant cardiac, renal or hepatic disease (as assessed by the site
             investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Huntsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Tang-Wai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doris Newmeyer</last_name>
    <phone>306-844-1208</phone>
    <email>doris.newmeyer@usask.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Supriya Arora</last_name>
    <email>supriya.arora@usask.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dory Sample</last_name>
      <email>dory.sample@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Tang-Wai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vesna Popovska</last_name>
      <email>vpopovska@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Linda Huh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A0G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Davies</last_name>
      <email>heather.davies@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Simard-Tremblay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Bitton</last_name>
      <email>jonathan.bitton@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Lionel Carmant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N5C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doris Newmeyer</last_name>
      <phone>306-844-1208</phone>
      <email>doris.newmeyer@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Huntsman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blair Seifert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Tellez-Zentino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Alcorn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Acton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Lyon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>June Lim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>December 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Richard Huntsman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Infantile Spasms</keyword>
  <keyword>Lennox Gastaut Syndrome</keyword>
  <keyword>Doose Syndrome</keyword>
  <keyword>Continuous Spike Wave in Sleep</keyword>
  <keyword>Landau-Kleffner Syndrome</keyword>
  <keyword>Dravet Syndrome</keyword>
  <keyword>Malignant Migrating Partial Seizures of Infancy (MMPSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
